Joby Aviation, Inc. (JOBY) came out with a quarterly loss of $0.24 per share versus the Zacks Consensus Estimate of a loss of $0.18. This compares to a loss of $0.18 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -33.33%. A quarter ago, it was expected that this company would post a loss of $0.18 per share when it actually produced a loss of $0.18, delivering no surprise.Over the last four quarters, the company has not been a ...

Group 1: Earnings Performance - Alamo Group reported quarterly earnings of $2.57 per share, missing the Zacks Consensus Estimate of $2.69 per share, but showing an increase from $2.35 per share a year ago [1] - The earnings surprise for the quarter was -4.46%, while the previous quarter saw a positive surprise of +13.73% with actual earnings of $2.65 compared to an expected $2.33 [2] - Over the last four quarters, the company has surpassed consensus EPS estimates two times [2] Group 2: Revenue Performance - The company posted revenues of $419.07 million for the quarter ended June 2025, exceeding the Zacks Consensus Estimate by 4.07% and slightly up from $416.3 million year-over-year [3] - Alamo Group has topped consensus revenue estimates only once over the last four quarters [3] Group 3: Stock Performance and Outlook - Alamo Group shares have increased approximately 21.6% since the beginning of the year, outperforming the S&P 500's gain of 7.1% [4] - The company's earnings outlook is crucial for investors, as it includes current consensus earnings expectations for upcoming quarters [5] - The estimate revisions trend for Alamo Group was mixed ahead of the earnings release, resulting in a Zacks Rank 3 (Hold) for the stock, indicating expected performance in line with the market [7] Group 4: Industry Context - The Manufacturing - Farm Equipment industry, to which Alamo Group belongs, is currently ranked in the bottom 21% of over 250 Zacks industries, which may impact stock performance [9] - Another company in the same industry, Deere, is expected to report a significant year-over-year earnings decline of -26.6% in its upcoming results [10][11]

分组1 - Kinetik Holdings Inc. reported quarterly earnings of $0.33 per share, exceeding the Zacks Consensus Estimate of $0.14 per share, but down from $0.54 per share a year ago, resulting in an earnings surprise of +135.71% [1] - The company posted revenues of $426.74 million for the quarter ended June 2025, missing the Zacks Consensus Estimate by 29.85%, compared to revenues of $359.46 million a year ago [2] - Kinetik Holdings has surpassed consensus EPS estimates only once in the last four quarters, indicating inconsistent performance [2] 分组2 - The stock has underperformed the market, losing about 25.7% since the beginning of the year, while the S&P 500 gained 7.1% [3] - The current consensus EPS estimate for the upcoming quarter is $0.34 on revenues of $689.08 million, and for the current fiscal year, it is $0.56 on revenues of $2.57 billion [7] - The Oil and Gas - Field Services industry, to which Kinetik belongs, is currently in the bottom 8% of the Zacks Industry Rank, suggesting a challenging environment for the stock [8]

Company Performance - MaxCyte, Inc. reported a quarterly loss of $0.12 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.10, and compared to a loss of $0.09 per share a year ago, indicating a decline in performance [1] - The company posted revenues of $8.51 million for the quarter ended June 2025, missing the Zacks Consensus Estimate by 14.93%, and down from $10.43 million in the same quarter last year [2] - Over the last four quarters, MaxCyte has surpassed consensus EPS estimates two times and topped consensus revenue estimates three times [2] Stock Performance - MaxCyte shares have lost approximately 50.5% since the beginning of the year, contrasting with the S&P 500's gain of 7.1% [3] - The current Zacks Rank for MaxCyte is 3 (Hold), indicating that the shares are expected to perform in line with the market in the near future [6] Earnings Outlook - The current consensus EPS estimate for the coming quarter is -$0.09 on revenues of $10.4 million, and for the current fiscal year, it is -$0.38 on revenues of $41.2 million [7] - The estimate revisions trend for MaxCyte was mixed ahead of the earnings release, which could change following the recent report [6] Industry Context - MaxCyte operates within the Medical - Biomedical and Genetics industry, which is currently ranked in the bottom 42% of over 250 Zacks industries, suggesting potential challenges ahead [8]

Group 1: Earnings Performance - Potbelly reported quarterly earnings of $0.09 per share, exceeding the Zacks Consensus Estimate of $0.08 per share, and showing an increase from $0.08 per share a year ago, representing an earnings surprise of +12.50% [1] - The company posted revenues of $123.71 million for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 0.99%, and an increase from year-ago revenues of $119.7 million [2] Group 2: Stock Performance and Outlook - Potbelly shares have increased approximately 17.7% since the beginning of the year, outperforming the S&P 500's gain of 7.1% [3] - The current consensus EPS estimate for the upcoming quarter is $0.09 on revenues of $119.1 million, and for the current fiscal year, it is $0.23 on revenues of $476 million [7] Group 3: Industry Context - The Retail - Restaurants industry, to which Potbelly belongs, is currently ranked in the bottom 32% of over 250 Zacks industries, indicating potential challenges for stock performance [8] - The performance of Potbelly's stock may be influenced by the overall outlook for the industry, as research indicates that the top 50% of Zacks-ranked industries outperform the bottom 50% by more than 2 to 1 [8]

Company Performance - Niagen Bioscience (NAGE) reported quarterly earnings of $0.04 per share, exceeding the Zacks Consensus Estimate of $0.02 per share, compared to break-even earnings per share a year ago, representing an earnings surprise of +100.00% [1] - The company posted revenues of $31.12 million for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 8.99%, and showing an increase from year-ago revenues of $22.74 million [2] - Niagen Bioscience has consistently outperformed consensus EPS and revenue estimates over the last four quarters [2] Stock Performance - Niagen Bioscience shares have increased approximately 72.7% since the beginning of the year, significantly outperforming the S&P 500's gain of 7.1% [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating it is expected to perform in line with the market in the near future [6] Future Outlook - The current consensus EPS estimate for the upcoming quarter is $0.03 on revenues of $30.95 million, and for the current fiscal year, it is $0.13 on revenues of $124.1 million [7] - The outlook for the Medical - Biomedical and Genetics industry, where Niagen Bioscience operates, is currently in the bottom 42% of over 250 Zacks industries, which may impact the stock's performance [8]

Tandem Diabetes Care, Inc. (TNDM) came out with a quarterly loss of $0.48 per share versus the Zacks Consensus Estimate of a loss of $0.4. This compares to a loss of $0.47 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -20.00%. A quarter ago, it was expected that this company would post a loss of $0.6 per share when it actually produced a loss of $0.67, delivering a surprise of -11.67%.Over the last four quarters, the company ...

Company Performance - Keros Therapeutics reported a quarterly loss of $0.76 per share, which was better than the Zacks Consensus Estimate of a loss of $1.14, and an improvement from a loss of $1.25 per share a year ago, representing an earnings surprise of +33.33% [1] - The company posted revenues of $18.17 million for the quarter ended June 2025, exceeding the Zacks Consensus Estimate by 135.95%, compared to revenues of $0.04 million in the same quarter last year [2] - Over the last four quarters, Keros Therapeutics has surpassed consensus EPS estimates two times and topped consensus revenue estimates two times [2] Stock Performance - Keros Therapeutics shares have declined approximately 9.1% since the beginning of the year, while the S&P 500 has gained 7.1% [3] - The current consensus EPS estimate for the upcoming quarter is -$1.08 on revenues of $4.37 million, and for the current fiscal year, it is $0.21 on revenues of $219 million [7] Industry Outlook - The Medical - Biomedical and Genetics industry, to which Keros Therapeutics belongs, is currently ranked in the bottom 42% of over 250 Zacks industries, indicating potential challenges ahead [8] - The performance of Keros Therapeutics may be influenced by the overall outlook of the industry, as research shows that the top 50% of Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1 [8]

Group 1: Earnings Performance - Aurora Cannabis Inc. reported a quarterly loss of $0.19 per share, compared to the Zacks Consensus Estimate of $0.18, and a loss of $0.11 per share a year ago, indicating an earnings surprise of -205.56% [1] - The company posted revenues of $75.49 million for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 6.50%, and compared to year-ago revenues of $67.27 million [2] - Over the last four quarters, Aurora Cannabis has surpassed consensus EPS estimates two times and topped consensus revenue estimates four times [2] Group 2: Stock Performance and Outlook - Aurora Cannabis shares have increased by approximately 8.2% since the beginning of the year, outperforming the S&P 500's gain of 7.1% [3] - The company's earnings outlook, including current consensus earnings expectations for upcoming quarters, will be crucial for investors [4] - The current consensus EPS estimate for the coming quarter is $0.09 on revenues of $65.3 million, and $0.56 on revenues of $272.14 million for the current fiscal year [7] Group 3: Industry Context - The Medical - Products industry, to which Aurora Cannabis belongs, is currently ranked in the bottom 41% of over 250 Zacks industries, indicating potential challenges for stock performance [8] - Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact investor decisions [5]

NewAmsterdam Pharma Company N.V. (NAMS) came out with a quarterly loss of $0.15 per share versus the Zacks Consensus Estimate of a loss of $0.52. This compares to a loss of $0.51 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of +71.15%. A quarter ago, it was expected that this company would post a loss of $0.45 per share when it actually produced a loss of $0.49, delivering a surprise of -8.89%.Over the last four quarters, the ...